Table 1.
Participant Characteristics Prior to Receiving Bamlanivimab Treatment by Participants Who Reported Presence (n = 91) or Absence (n = 415) of Overall Coronavirus Disease 2019 Symptoms on Global Assessment at Week 24
| Characteristic | Global Assessment: Overall COVID-19 Symptoms | ||
|---|---|---|---|
| Present (n = 91) | Absent (n = 415) | Total (N = 506) | |
| Age, y, median (quartiles) | 52 (43, 60) | 50 (40, 61) | 51 (40, 60) |
| Female sex | 59 (65) | 196 (47) | 255 (50) |
| Cisgender | 89 (98) | 413 (100) | 502 (99) |
| Race | |||
| White | 82 (90) | 370 (89) | 452 (89) |
| Asian | 3 (3) | 15 (4) | 18 (4) |
| Black or African American | 5 (5) | 19 (5) | 24 (5) |
| American Indian or Alaska Native | 0 (0) | 1 (0) | 1 (0) |
| Native Hawaiian or other Pacific Islander | 1 (1) | 1 (0) | 2 (0) |
| Multiple | 0 (0) | 2 (0) | 2 (0) |
| Other | 0 (0) | 7 (2) | 7 (1) |
| Hispanic/Latino ethnicity | 20 (22) | 164 (40) | 184 (36) |
| BMI, kg/m2, median (quartiles) | 30.4 (26.0, 34.8) | 28.2 (25.1, 32.7) | 28.4 (25.2, 33.5) |
| Cigarette smoking status | |||
| Current | 10 (11) | 15 (4) | 25 (5) |
| Former | 15 (16) | 71 (17) | 86 (17) |
| Never | 66 (73) | 329 (79) | 365 (78) |
| Reported ≥1 high-risk comorbiditya | 55 (60) | 217 (5) | 272 (54) |
| SARS-CoV-2 vaccination | 0 (0) | 2 (<0.5) | 2 (<0.5) |
| Symptom duration at enrollment, d, median (quartiles) | 5 (4, 7) | 5 (4, 7) | 5 (4, 7) |
| ≤5 d | 51 (56) | 225 (54) | 276 (55) |
| >5 d | 40 (44) | 190 (46) | 230 (45) |
| SARS-CoV-2 RNA from AN swabs, log10 copies/mL, median (quartiles) | 5.4 (3.3, 6.8) | 5.6 (3.2, 6.9) | 5.5 (3.3, 6.9) |
| <LLoQ | 12 (13) | 56 (14) | 68 (14) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AN, anterior nasal; BMI, body mass index; COVID-19, coronavirus disease 2019; LLoQ, lower limit of quantification; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
High-risk comorbidities include active cancer, moderate to severe asthma, chronic kidney disease, chronic liver disease, history of cirrhosis, chronic lung disease, current smoker, cardiovascular disease, diabetes, hypertension, treatment with biologics/immunomodulators/cancer chemotherapy within 90 days of entry, human immunodeficiency virus with CD4 count <200 cells/μL, receiving corticosteroids within 30 days of entry, and obesity.